Octreotide vs Pasireotide
Overview
Octreotide and Pasireotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Octreotide and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Octreotide | Pasireotide | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | Every 4 weeks (LAR); two to four times daily (immediate-release) | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. Octreotide is categorised under Hormonal, while Pasireotide falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Octreotide: FDA-approved. Pasireotide: FDA-approved.
Dosing. Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking Octreotide and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Octreotide and Pasireotide?
- Octreotide and Pasireotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Octreotide is FDA-approved for one or more indications, whereas Pasireotide is FDA-approved for one or more indications.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take Octreotide and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking Octreotide and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Octreotide or Pasireotide FDA-approved?
- Octreotide is FDA-approved for one or more indications. Pasireotide is FDA-approved for one or more indications.
Read the full articles
- Octreotide — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references